Related Experiment Videos
Minnelide, a novel drug for pancreatic and liver cancer
Sulagna Banerjee1, Ashok Saluja2
1Division of Basic and Translational Research, Dept. of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.
Background:
Pancreatic cancer is the 10th leading cause of all new cancer cases for men and the fourth leading cause of death across genders, having very poor prognosis and survival rates. The current standard of care Gemcitabine fails to add any survival benefit for this disease (www.cancer.gov). Though the incidence of pancreatic cancer is found to be higher in developed countries, the aggressive biology of the cancer, its high rate of recurrence and chemo-resistance make it a formidable disease in all parts of the globe. Hepatocellular carcinoma (HCC) or liver cancer, on the other hand affects almost 750,000 people world wide with 84% of the cases coming from underdeveloped or developing countries
Results:
Our studies show that Minnelide, a water soluble pro-drug of triptolide (active compound from a chinese herb) is very effective against a number of malignant diseases.
Conclusion:
The current study discusses the efficacy of this compound in pancreatic and liver cancer.
Insights
Minnelide, a triptolide derivative, shows significant efficacy against pancreatic cancer and hepatocellular carcinoma (HCC). This novel compound offers a promising therapeutic avenue for these aggressive malignancies, addressing limitations of current treatments.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Pancreatic cancer is a leading cause of cancer death with poor prognosis and chemo-resistance.
- Hepatocellular carcinoma (HCC) disproportionately affects developing nations.
- Current standard treatments, like Gemcitabine, offer limited survival benefits for pancreatic cancer.
Purpose of the Study:
- To evaluate the efficacy of Minnelide, a water-soluble triptolide pro-drug, in treating pancreatic and liver cancers.
- To investigate a potential new therapeutic agent for aggressive malignancies with poor outcomes.
Main Methods:
- Preclinical studies were conducted to assess Minnelide's effectiveness.
- The study focused on Minnelide's activity against pancreatic and hepatocellular carcinoma models.
Main Results:
- Minnelide demonstrated significant efficacy in preclinical models of various malignant diseases.
- The compound's water-soluble nature facilitates its administration and potential therapeutic use.
Conclusions:
- Minnelide exhibits potent anti-cancer activity, suggesting its potential as a novel treatment for pancreatic and liver cancers.
- Further research into Minnelide is warranted to explore its clinical application for these challenging diseases.